TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25911881

Group type: EXPERIMENTAL
Intervention: HAIC (Hepatic artery infusion chemotherapy) - 5‐FU 1000 mg/m2 on day 1, Oxaliplatin 85 mg/m2 on day 1, Gemcitabine 1000 mg/m2 on day 1 and 8, starting 3 weeks after operation with intervals of 4 weeks.
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 85
Study: 23357657

Group type: EXPERIMENTAL
Intervention: Internet-delivered behavioral activation combined with acceptance and commitment therapy (ACT) for 8 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 80
Study: 21282809

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) added to general exercise training
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle endurance training
Number of subjects: 32
Study: 17635971

Group type: EXPERIMENTAL
Intervention: Epidural blood patch (EDBP)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 42
Study: 16476809

Group type: EXPERIMENTAL
Intervention: etilevodopa-carbidopa
Number of subjects: 327

Group type: COMPARATOR
Intervention: levodopa-carbidopa
Number of subjects: 327
Study: 15226212

Group type: EXPERIMENTAL
Intervention: Postmenopausal hormone therapy (PHT)
Number of subjects: 423

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 423
Study: 11789166

Group type: EXPERIMENTAL
Intervention: Chanbei Kechuanping (CBKCP)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Guilong Kechuanning (Control)
Number of subjects: 96
Study: 8697552

Group type: EXPERIMENTAL
Intervention: Edrophonium 0.05 mg.kg‐1
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Edrophonium 0.1 mg.kg‐1
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Edrophonium 0.5 mg.kg‐1
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Edrophonium 1.0 mg.kg‐1
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo (Edrophonium 0.0 mg.kg‐1)
Number of subjects: 75
Study: 2003848

Group type: EXPERIMENTAL
Intervention: Medication communication skills program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medication education program
Number of subjects: 0
Study: 6224928

Group type: EXPERIMENTAL
Intervention: Biofeedback-assisted relaxation and cognitive imagery treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Attention-comparison group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Medical control group
Number of subjects: 30
Study: 31769729

Group type: EXPERIMENTAL
Intervention: Qualitative interviews with primary care providers
Number of subjects: 11
Study: 30377381

Group type: EXPERIMENTAL
Intervention: TAU augmented with TCT (30 hours)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 45
Study: 28982774

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 μg plus fluticasone propionate 500 μg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Salmeterol 50 μg
Number of subjects: 60
Study: 26537393

Group type: EXPERIMENTAL
Intervention: Live demonstration (group A)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Procedural video (group B)
Number of subjects: 49
Study: 23653047

Group type: EXPERIMENTAL
Intervention: Voriconazole, administered twice daily orally
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intravenous voriconazole
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no pretreatment)
Number of subjects: 10
Study: 21393310

Group type: EXPERIMENTAL
Intervention: Active arm (169 babies) - attended workshops and promoted implementation of research evidence
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control arm (186 babies) - dissemination of research report and information
Number of subjects: 180
Study: 19375681

Group type: EXPERIMENTAL
Intervention: 100 units IA-BoNT/A + lidocaine
Number of subjects: 43

Group type: COMPARATOR
Intervention: IA-saline + lidocaine
Number of subjects: 43
Study: 17905167

Group type: EXPERIMENTAL
Intervention: IPS (Individual Placement and Support)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Vocational services
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: IPS
Number of subjects: 312
Study: 15471151

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 11410822

Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg three times daily
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo three times daily
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Weight maintenance or regain
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 51
Study: 9757157

Group type: EXPERIMENTAL
Intervention: Concentration-controlled zidovudine regimen
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard fixed-dose zidovudine (500 mg/day)
Number of subjects: 20
Study: 7832680

Group type: EXPERIMENTAL
Intervention: GS-80 amalgam alloy
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Lojic+ amalgam alloy
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Permite C amalgam alloy
Number of subjects: 301

Group type: COMPARATOR
Intervention: Dispersalloy, Valiant PhD, Lojic N
Number of subjects: 301
Study: 3072961

Group type: EXPERIMENTAL
Intervention: Health Survey Questionnaire (HSQ)
Number of subjects: 4203
Study: 31658212

Group type: EXPERIMENTAL
Intervention: Goal Setting and Implementation Planning (GSIP) intervention
Number of subjects: 20

Group type: COMPARATOR
Intervention: Passive control arm
Number of subjects: 20
Study: 28506013

Group type: EXPERIMENTAL
Intervention: Standardized equipment-free exercise program (delivered by qualified fitness instructors)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 92
Study: 25033106

Group type: EXPERIMENTAL
Intervention: Invasive management without stents (thrombectomy to restore TIMI 3 flow)
Number of subjects: 101
Study: 23636098

Group type: EXPERIMENTAL
Intervention: Platelet transfusion over 30 minutes
Number of subjects: 43

Group type: COMPARATOR
Intervention: Platelet transfusion over 120 minutes
Number of subjects: 43
Study: 21562125

Group type: EXPERIMENTAL
Intervention: Aerosolized albuterol (5 mg) every 4 hours for up to 10 days
Number of subjects: 282

Group type: COMPARATOR
Intervention: Saline placebo every 4 hours for up to 10 days
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Aerosolized albuterol (5 mg)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 282
Study: 19484320

Group type: EXPERIMENTAL
Intervention: Telemedicine (TM) consultation
Number of subjects: 26

Group type: COMPARATOR
Intervention: In-person (IP) consultation
Number of subjects: 26
Study: 16500364

Group type: COMPARATOR
Intervention: 50 mg of clomiphene citrate alone (group A, n = 65)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: 50 mg of clomiphene citrate plus hCG (group B, n = 60)
Number of subjects: 125
Study: 12670067

Group type: EXPERIMENTAL
Intervention: Indirect adhesive composite configurations with and without adhesive fiber posts
Number of subjects: 6

Group type: COMPARATOR
Intervention: Adhesive composite onlays on 'vital' teeth (control)
Number of subjects: 6
Study: 12879121

Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard NSAIDs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8615729

Group type: EXPERIMENTAL
Intervention: PCA morphine
Number of subjects: 92

Group type: COMPARATOR
Intervention: IM morphine
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: IM ketorolac
Number of subjects: 92
Study: 1292340

Group type: COMPARATOR
Intervention: High-flux hemodialysis
Number of subjects: 22
Study: 6537870

Group type: EXPERIMENTAL
Intervention: Isolated soy protein (Supro‐620)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Egg protein
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Isolated soy protein with 1.6% L‐methionine supplementation
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Isolated soy protein with 1.1% L‐methionine supplementation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Unsupplemented egg protein
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Isolated soy protein with methionine supplementation
Number of subjects: 24
Study: 31221620

Group type: EXPERIMENTAL
Intervention: MRI screening (annual MRI and clinical breast examination plus biennial mammography)
Number of subjects: 1355

Group type: EXPERIMENTAL
Intervention: MRI screening
Number of subjects: 1355

Group type: COMPARATOR
Intervention: Mammography screening
Number of subjects: 1355
Study: 30459247

Group type: EXPERIMENTAL
Intervention: Fasiglifam
Number of subjects: 3207

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3207
Study: 26937646

Group type: EXPERIMENTAL
Intervention: CartiJoint Forte (two tablets daily for 8 weeks)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 24065463

Group type: EXPERIMENTAL
Intervention: AAV1/SERCA2a high-dose (1×10(13) DNase-resistant particles)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: AAV1/SERCA2a low-dose (6×10(11) DNase-resistant particles)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: AAV1/SERCA2a mid-dose (3×10(12) DNase-resistant particles)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 22520658

Group type: EXPERIMENTAL
Intervention: Nurse-led clinic in primary care (PCC)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Hospital-based childhood obesity clinic (BRHC)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Both trial arms (PCC and BRHC)
Number of subjects: 76
Study: 19810664

Group type: EXPERIMENTAL
Intervention: Clinical simulation in nursing education, replacing some early-term clinical placement hours with simulated clinical experience.
Number of subjects: 54

Group type: COMPARATOR
Intervention: Clinical control group with all normally scheduled clinical hours.
Number of subjects: 54
Study: 18480923

Group type: EXPERIMENTAL
Intervention: NB‐UVB plus antihistamine
Number of subjects: 81

Group type: COMPARATOR
Intervention: Antihistamine (control)
Number of subjects: 81
Study: 15737948

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (loading dose of 100 mg followed by continuous infusion of 0.18 mg/kg/h for 6 days)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Continuous veno-venous hemofiltration (CVVH)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No CVVH
Number of subjects: 24
Study: 12531659

Group type: EXPERIMENTAL
Intervention: Closed reduction and Kirschner wire fixation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Open reduction and lag screw fixation
Number of subjects: 32
Study: 9440408

Group type: EXPERIMENTAL
Intervention: Breathing exercises in the rehabilitation group
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 81
Study: 8531610

Group type: EXPERIMENTAL
Intervention: DIET/STTI
Number of subjects: 4

Group type: COMPARATOR
Intervention: CONTROL
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: STTI
Number of subjects: 4
Study: 2142271

Group type: EXPERIMENTAL
Intervention: Intracutaneous injections of sterile water
Number of subjects: 45

Group type: COMPARATOR
Intervention: Subcutaneous injections of isotonic saline (placebo)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 45
Study: 699486

Group type: EXPERIMENTAL
Intervention: Ibuprofen (600 mg orally)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 0
Study: 31930845

Group type: EXPERIMENTAL
Intervention: Olive Leaf Extract (OLE)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 28865430

Group type: EXPERIMENTAL
Intervention: 12-week aerobic training intervention
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group with no additional training
Number of subjects: 88
Study: 26686681

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 55) received three face-to-face individual PA consultations
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group (n = 54)
Number of subjects: 109
Study: 24570490

Group type: EXPERIMENTAL
Intervention: Landiolol (n=68)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Non‐landiolol (control, n=68)
Number of subjects: 136
Study: 21484276

Group type: EXPERIMENTAL
Intervention: Dihydrotetrabenazine ([(3)H]TBZOH) binding in children with MDD
Number of subjects: 14

Group type: COMPARATOR
Intervention: Matched controls (N=16)
Number of subjects: 14
Study: 18087034

Group type: EXPERIMENTAL
Intervention: Culturally-focused counseling in all-African-American groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conventional counseling in all-African-American groups
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional counseling in racially-mixed groups
Number of subjects: 0

Group type: COMPARATOR
Intervention: All counseling options
Number of subjects: 0
Study: 16508777

Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/day)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 14550687

Group type: EXPERIMENTAL
Intervention: Neuronavigated 1 Hz rTMS
Number of subjects: 3

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 3
Study: 11418517

Group type: EXPERIMENTAL
Intervention: Itraconazole oral solution 100 mg bd
Number of subjects: 277

Group type: COMPARATOR
Intervention: Amphotericin B 500 mg tds plus nystatin 2 MU qds
Number of subjects: 277
Study: 9596317

Group type: EXPERIMENTAL
Intervention: Conventional medical therapy plus NPPV
Number of subjects: 27

Group type: COMPARATOR
Intervention: Conventional medical therapy alone
Number of subjects: 27
Study: 8042719

Group type: EXPERIMENTAL
Intervention: propofol/fentanyl (4-8 mg.kg‐1.h‐1, 1.2 mg.h‐1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: isoflurane/fentanyl (0.6-1.2 vol%, 1.2 mg.h‐1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: flunitrazepam/fentanyl (1.2 mg.h‐1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: surgical stimulation (skin incision, sternotomy)
Number of subjects: 30
Study: 2847928

Group type: EXPERIMENTAL
Intervention: Clonidine 0.45 mg daily for three days
Number of subjects: 45
Study: 7938559

Group type: EXPERIMENTAL
Intervention: SC 48,274 1mg
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: SC 48,274 25mg
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 84148

Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (800 mg daily)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sulphasalazine (2 g daily)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combination of disodium cromoglycate and sulphasalazine
Number of subjects: 120
Study: 30671722

Group type: EXPERIMENTAL
Intervention: Improved solid fuel stoves and clean cooking options (LPG and induction stoves)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental treatments (stove exchanges and free stoves)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Free stoves
Number of subjects: 0
Study: 29735484

Group type: EXPERIMENTAL
Intervention: Inclisiran 200 mg single-dose
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Inclisiran 300 mg 2-dose
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Inclisiran 500 mg single-dose
Number of subjects: 501

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 501
Study: 26822398

Group type: EXPERIMENTAL
Intervention: Afatinib plus vinorelbine (40 mg/day afatinib + 25 mg/m² vinorelbine per week)
Number of subjects: 508

Group type: COMPARATOR
Intervention: Trastuzumab plus vinorelbine (2 mg/kg trastuzumab per week after 4 mg/kg loading dose + 25 mg/m² vinorelbine per week)
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Afatinib plus vinorelbine
Number of subjects: 508
Study: 25707822

Group type: EXPERIMENTAL
Intervention: Mechanical method (specific toothbrush and dentifrice)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Chemical method (2% R. communis solution)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combined method (Mechanical + Chemical)
Number of subjects: 30
Study: 22594388

Group type: EXPERIMENTAL
Intervention: Back School (active therapy, ergonomics, and education)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Passive physiotherapy (control)
Number of subjects: 124
Study: 18834700

Group type: EXPERIMENTAL
Intervention: Educational workshop consisting of eight 180-minute training sessions over four months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 40
Study: 17878765

Group type: EXPERIMENTAL
Intervention: Iontophoretic application of ACh
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Iontophoretic application of SNP
Number of subjects: 40
Study: 15084209

Group type: EXPERIMENTAL
Intervention: Edited alpha1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Unedited alpha1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Unedited alpha1 in general population
Number of subjects: 40

Group type: COMPARATOR
Intervention: Alpha1 reduction due to premature beats
Number of subjects: 40
Study: 11965272

Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia and postoperative epidural analgesia for 72 hours with general anaesthesia
Number of subjects: 915

Group type: COMPARATOR
Intervention: Control (alternative analgesic regimens with general anaesthesia)
Number of subjects: 915

Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia
Number of subjects: 915

Group type: EXPERIMENTAL
Intervention: Postoperative epidural analgesia
Number of subjects: 915
Study: 9701893

Group type: EXPERIMENTAL
Intervention: Uncooked rice ORS
Number of subjects: 70

Group type: COMPARATOR
Intervention: WHO-ORS
Number of subjects: 70
Study: 7907893

Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ebastine
Number of subjects: 0
Study: 2698241

Group type: EXPERIMENTAL
Intervention: Optrex Eye Lotion (self-administered by irrigation into the left eye three times daily for seven days)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Optrex Eye Lotion (self-administered in the right eye by 15 patients)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Optrex Eye Lotion
Number of subjects: 24
Study: 183554

Group type: EXPERIMENTAL
Intervention: Metronidazole (750 mg three times daily for 5 days)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Tinidazole (1 g twice daily on 2 consecutive days)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Starch placebo
Number of subjects: 115
Study: 31418168

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101

Group type: COMPARATOR
Intervention: No premedication
Number of subjects: 101
Study: 28328234

Group type: EXPERIMENTAL
Intervention: Basal insulin peglispro (BIL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Human insulin (HI)
Number of subjects: 0
Study: 25354751

Group type: EXPERIMENTAL
Intervention: Active rTMS (10 Hz stimulation of the bilateral dorsolateral prefrontal cortex for 3 weeks)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 32
Study: 23857221

Group type: EXPERIMENTAL
Intervention: Metformin (1.5-2.5 g per day)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 20528207

Group type: EXPERIMENTAL
Intervention: Metformin plus low-dose oral contraceptive (ethinyl oestradiol-cyproterone acetate, EE/CA) 850 mg metformin twice a day for three cycles
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (non-PCOS subjects)
Number of subjects: 60
Study: 19423131

Group type: EXPERIMENTAL
Intervention: Alprazolam and investigational compound
Number of subjects: 211

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study: 16412864

Group type: EXPERIMENTAL
Intervention: Atrial pacing at 75 beats/min
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (pacing turned off)
Number of subjects: 15
Study: 15255788

Group type: EXPERIMENTAL
Intervention: Low-dose dopamine (5 micro g kg(‐1) min(‐1))
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (5% glucose solution)
Number of subjects: 14
Study: 10675425

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 19
Study: 9411510

Group type: EXPERIMENTAL
Intervention: Turbo STIR (T-STIR) sequence
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional STIR sequence
Number of subjects: 20
Study: 8244916

Group type: EXPERIMENTAL
Intervention: 12 micrograms formoterol
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 24 micrograms formoterol
Number of subjects: 13

Group type: COMPARATOR
Intervention: 200 micrograms salbutamol
Number of subjects: 13
Study: 3516608

Group type: EXPERIMENTAL
Intervention: Aspirin plus dipyridamole
Number of subjects: 231

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study: 29273827

Group type: EXPERIMENTAL
Intervention: Eldecalcitol (ELD; 0.75 μg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1α hydroxyl calcidiol (ALF; 1 μg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Plain vitamin D3 (800 IU/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 28167659

Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg orally once daily until progression or unacceptable toxicity
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 63
Study: 26272523

Group type: EXPERIMENTAL
Intervention: High mean SAI QRST (third tertile)
Number of subjects: 234
Study: 23679113

Group type: EXPERIMENTAL
Intervention: Live induction
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Recorded induction
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control
Number of subjects: 39
Study: 21446892

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg
Number of subjects: 1385

Group type: COMPARATOR
Intervention: Atorvastatin 80 mg
Number of subjects: 1385

Group type: EXPERIMENTAL
Intervention: Both statins
Number of subjects: 1385
Study: 17938986

Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg daily
Number of subjects: 759

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 759
Study: 16542484

Group type: EXPERIMENTAL
Intervention: AVP/norepinephrine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Norepinephrine alone
Number of subjects: 18
Study: 12802880

Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg)
Number of subjects: 20